{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:55:18Z","timestamp":1758970518180,"version":"3.40.5"},"reference-count":49,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Lipoprotein(a) (Lp[a]) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin\/kexin\u20109 monoclonal antibodies (PCSK9mAbs) can lower Lp(a) levels in clinical trials, but their effects in patients with elevated Lp(a) in clinical practice remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate the effectiveness and safety of PCSK9mAbs in lowering plasma Lp(a) in patients with elevated Lp(a) concentrations in a lipid clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an open\u2010label study of 53 adult patients with elevated Lp(a) concentration (\u22650.5\u00a0g\/L). Clinical, biochemical, and safety data were collected before and on treatment with evolocumab or alirocumab over a mean period of 11\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with a PCSK9mAb resulted in a significant reduction of 0.29 g\/L (\u221222%) in plasma Lp(a) concentration (p&lt;.001). There were also significant reductions in low\u2010density lipoprotein\u2010cholesterol (LDL\u2010C) (\u221253%), remnant\u2010cholesterol (\u221212%) and apolipoprotein B (\u221243%) concentrations. The change in Lp(a) concentration was significantly different from a comparable group of 35 patients with elevated Lp(a) who were not treated with a PCSK9mAb (\u221222% vs. \u22122%, p&lt;.001). The reduction in Lp(a) concentration was not associated with the corresponding changes in LDL\u2010C, remnant\u2010cholesterol, and apolipoprotein B (p&gt;.05 in all). 7.5% and 47% of the patients attained a target concentration of Lp(a) &lt;0.5\u00a0g\/L and LDL\u2010C &lt;1.8\u2009mmol\/L, respectively. PCSK9mAbs were well tolerated, the common adverse effects being pharyngitis (9.4%), nasal congestion (7.6%), myalgia (9.4%), diarrhoea (7.6%), arthralgia (9.4%) and injection site reactions (11%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PCSK9mAbs can effectively and safely lower plasma Lp(a) concentrations in patients with elevated Lp(a) in clinical practice; the impact of the fall in Lp(a) on ASCVD outcomes requires further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.23607","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T05:24:19Z","timestamp":1620365059000},"page":"805-813","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of proprotein convertase subtilisin\/kexin\u20109 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic"],"prefix":"10.1002","volume":"44","author":[{"given":"Anindita","family":"Chakraborty","sequence":"first","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences University of Western Australia  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences University of Western Australia  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-5197","authenticated-orcid":false,"given":"Dick C.","family":"Chan","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences University of Western Australia  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Barnett","sequence":"additional","affiliation":[{"name":"Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology Royal Perth Hospital  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Woodward","sequence":"additional","affiliation":[{"name":"Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology Royal Perth Hospital  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Vorster","sequence":"additional","affiliation":[{"name":"Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology Royal Perth Hospital  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences University of Western Australia  Perth Australia"},{"name":"Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology Royal Perth Hospital  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R071233"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.04.010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.10.011"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R067314"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30088-8"},{"key":"e_1_2_8_8_1","first-page":"158869","article-title":"Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease","volume":"2021","author":"Bigazzi F","year":"1866","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31652-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30042-0"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.063"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R053066"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800091-JLR200"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz430"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P065334"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.09.010"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13032"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.314191"},{"key":"e_1_2_8_22_1","first-page":"137","article-title":"PCSK9 inhibitors in familial hypercholesterolaemia: a real\u2010world experience and meta\u2010analysis","volume":"26","author":"Deshmukh H","year":"2019","journal-title":"Br J Cardiol"},{"key":"e_1_2_8_23_1","unstructured":"The pharmaceutical benefits scheme (PBS) 2020 (Available from):https:\/\/www.pbs.gov.au\/medicine\/item\/10958R-1193D-1484K-1485L-1972D-1977J-1985T-1986W."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.08.146"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-016-0211-y"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.05.036"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015355"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa649"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318792626"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy122"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903849106"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072103"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308811"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001969"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.060"},{"key":"e_1_2_8_37_1","article-title":"Discordant responses of plasma low\u2010density lipoprotein cholesterol and lipoprotein(a) to alirocumab: a pooled analysis from 10 ODYSSEY phase 3 studies","volume":"204748732091580","author":"Mahmood T","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.03.001"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010932"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.11.003"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1193"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz310"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701131"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.312951"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.1470"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154221"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025080"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clc.23607","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:45:11Z","timestamp":1693291511000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.23607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/clc.23607"],"URL":"https:\/\/doi.org\/10.1002\/clc.23607","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"type":"print","value":"0160-9289"},{"type":"electronic","value":"1932-8737"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"2021-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}